Lumosa Therapeutics Co., Ltd. received approval to initiate phase 2, Multiple-dose study of its LT3001, a Novel Treatment for Acute Ischemic Stroke, Across All Six European Countries. Planned development stages: Phase 2, Phase 3, NDA. Current development stage: Application submission/approval/disapproval/each of clinical trials (include interim analysis): The multiple-dose Phase 2 clinical trial for LT3001 was approved for execution by the US FDA, Taiwan FDA, and the six European countries (Germany, Spain, Italy, Czechia, Greece, and Portugal).

After obtaining official approval or the results of statistically significant sense, the future strategy: N/A. Accumulated investment expenditure incurred: Due to the sensitive nature of future international licensing negotiations, and to safeguard the interest of the investors and prevent any potential impact on the licensing amount, relevant information is not disclosed at this time. Upcoming development plan: Estimated date of completion: The enrollment of the Phase 2 study for LT3001 is expected to be completed within 12 months. The actual timeline depends on the recruitment progress.

According to the agreement between Lumosa and the inventors of LT3001, the Company will pay 5% of the licensing income and 2% of the net sales revenue if the LT3001 is successfully out-licensed.